Can Remicade (infliximab) cause arterial thrombosis or increase atherosclerosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Remicade Does Not Cause Arterial Thrombosis and May Actually Reduce Atherosclerotic Risk in Inflammatory Conditions

Remicade (infliximab) does not cause arterial thrombosis or increase atherosclerosis; rather, it is specifically recommended as first-line treatment for arterial involvement in inflammatory vasculitis and may reduce atherosclerotic cardiovascular risk by controlling systemic inflammation. The evidence demonstrates that infliximab treats—rather than causes—arterial thrombosis in appropriate clinical contexts.

Evidence from Guidelines: Infliximab as Treatment for Arterial Disease

The most recent and authoritative evidence comes from the 2025 EULAR guidelines for Behçet's syndrome, which recommend infliximab as first-line treatment specifically for arterial involvement, including arterial aneurysms and thrombosis 1. This represents a major shift from 2018 recommendations, based on:

  • An RCT showing infliximab provided higher remission rates compared to cyclophosphamide at week 24 in patients with arterial aneurysms and/or thrombosis 1
  • Lower frequency of mild and moderate adverse events with infliximab compared to cyclophosphamide 1
  • Retrospective studies demonstrating high remission and low relapse rates with long-term infliximab use for vascular involvement 1

The guidelines explicitly state infliximab should be continued for at least 5 years as maintenance therapy for arterial involvement 1, which would be contraindicated if the drug itself promoted arterial thrombosis.

Cardiovascular Safety Profile from FDA Labeling

The FDA-approved prescribing information for Remicade includes a specific warning about cardiovascular events, but this is limited to worsening heart failure in patients with moderate-to-severe heart failure (NYHA class III/IV) 2. The label specifically contraindicates doses >5 mg/kg in this population 2.

Importantly, the FDA label documents cardiovascular and cerebrovascular reactions (cerebrovascular accidents, myocardial infarctions, arrhythmias) occurring during and within 24 hours of infusion 2, but these are acute infusion-related events, not chronic atherosclerotic disease progression. The label does not list arterial thrombosis or atherosclerosis acceleration as adverse effects 2.

Distinguishing Context: When Infliximab Should NOT Be Used

The 2021 AHA/ASA stroke prevention guidelines provide critical context: infliximab should NOT be used to treat giant cell arteritis 3. A phase II trial showed patients receiving infliximab had higher risk of disease activity and lower chances of remission compared to placebo 3. This is disease-specific and does not indicate infliximab causes arterial thrombosis—rather, it is simply ineffective for this particular vasculitis.

Research Evidence: Mixed but Generally Protective

The research literature presents nuanced findings:

Potentially Protective Effects:

  • A 2012 RCT showed infliximab plus methotrexate caused significantly greater reduction in pulse wave velocity (a marker of arterial stiffness) compared to methotrexate alone in early rheumatoid arthritis, suggesting prevention of atherosclerosis progression by improving vascular function 4
  • A 2026 review notes that while some RA treatments may aggravate atherogenesis, biologics including infliximab can reduce atherosclerotic risk by modulating inflammatory pathways 5

Concerning Findings:

  • One small 2009 study (n=14) reported worsening intima-media thickness in 7 RA patients treated with infliximab over 12 months compared to 7 controls 6
  • A 2013 case report described acute renal artery occlusion 3 days after first infliximab infusion for ulcerative colitis, though extensive workup found no other predisposing factors 7
  • Laboratory studies show anti-infliximab antibodies can neutralize infliximab's protective effects on coronary endothelial cells stimulated by inflammatory cytokines 8

Clinical Interpretation and Practical Guidance

The weight of evidence, particularly from high-quality guidelines, indicates infliximab does not cause arterial thrombosis or accelerate atherosclerosis. The apparent contradiction in the literature reflects:

  1. Disease-specific effects: Infliximab treats arterial involvement in Behçet's syndrome [1-1] but is ineffective in giant cell arteritis 3

  2. Inflammation vs. drug effect: Uncontrolled systemic inflammation in RA and inflammatory bowel disease independently drives atherosclerosis. Effective anti-inflammatory therapy generally reduces cardiovascular risk, though the 2009 study 6 suggests individual variability

  3. Rare idiosyncratic events: The single case report of renal artery thrombosis 7 likely represents an extremely rare idiosyncratic reaction rather than a class effect

Key Caveats:

  • Heart failure patients: Avoid infliximab doses >5 mg/kg in moderate-to-severe heart failure (NYHA class III/IV) due to documented increased mortality risk 9, 2

  • Acute infusion reactions: Monitor during infusion for cardiovascular events (MI, arrhythmias, stroke) that can occur within 24 hours 2

  • Anti-drug antibodies: Development of anti-infliximab antibodies may reduce efficacy and potentially negate vascular protective effects 8

  • Individual risk assessment: In patients with established atherosclerotic disease, weigh the cardiovascular benefits of controlling systemic inflammation against theoretical concerns, recognizing that untreated inflammation likely poses greater vascular risk

In summary, Remicade does not cause arterial thrombosis or increase atherosclerosis in the general population and is specifically indicated for treating arterial involvement in certain vasculitides. The primary cardiovascular concern is worsening heart failure in susceptible patients, not arterial thrombotic disease.

Related Questions

In a patient after coronary artery bypass grafting for multivessel coronary artery disease who is on aspirin 81 mg daily and rivaroxaban (Xarelto) 2.5 mg twice daily, is additional pharmacologic DVT prophylaxis required?
Can rivaroxaban 2.5 mg twice daily be substituted with apixaban (Eliquis) 2.5 mg twice daily for dual‑pathway therapy in chronic coronary artery disease or symptomatic peripheral artery disease?
What are the common causes of recurrent arterial thrombosis?
What is the recommended treatment for coronary vasculitis in a patient with rheumatoid arthritis?
How should antithrombotic therapy be managed in an 85-year-old male with acute cerebrovascular accident, atrial fibrillation, coronary artery disease, and a gastrointestinal bleed who is currently on clopidogrel (Plavix), aspirin, and apixaban (Eliquis)?
Can heavy lifting precipitate a pneumothorax in adults, especially those with underlying lung disease?
Can non‑typhoidal Salmonellae cause a bowel fistula?
In a patient with rheumatoid arthritis experiencing an acute mono‑articular flare and not taking any other arthritis medications, what acute steroid regimen should be used?
What are the differential diagnoses for folliculitis in a patient with chronic kidney disease?
Is bilateral renal artery stenosis a contraindication for Entresto (sacubitril/valsartan)?
When is Montelukast indicated, and what are the dosing and monitoring recommendations for patients with allergic cough, allergic rhinitis, or mild asthma?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.